Sanofi-Aventis To Begin Long-Term Acomplia Cardio Safety Study By Fall
Executive Summary
Sanofi-Aventis will begin conducting a four-to-five year Acomplia (rimonabant) cardiovascular safety study by the fall, the company said
You may also be interested in...
Zimulti Loses On Weight Loss; Sanofi May Try Diabetes Route To Get Approval
If FDA concurs with the Endocrinologic and Metabolic Drugs Advisory Committee's negative opinion of the pending obesity indication for Zimulti (rimonabant), Sanofi-Aventis may have another attempt at bringing the drug to market for type 2 diabetes
Zimulti Loses On Weight Loss; Sanofi May Try Diabetes Route To Get Approval
If FDA concurs with the Endocrinologic and Metabolic Drugs Advisory Committee's negative opinion of the pending obesity indication for Zimulti (rimonabant), Sanofi-Aventis may have another attempt at bringing the drug to market for type 2 diabetes
Sanofi Feels The Weight Of FDA’s “Approvable” Letter For Rimonabant
FDA is not requesting additional clinical trials for Acomplia's weight loss indication, Sanofi-Aventis said Feb. 24 during its investors meeting in Paris